Lutetium 177 PSMA Therapy | Advanced Prostate Cancer Treatment at KUTRRH
Kenyatta University Teaching, Referral & Research Hospital (KUTRRH) has achieved a remarkable medical breakthrough—becoming the first public hospital in East Africa to offer Lutetium‑177 PSMA targeted radiation therapy, an innovative treatment giving new hope to patients with advanced prostate cancer.
This milestone strengthens KUTRRH’s position as a regional leader in modern cancer treatment and expands access to life-extending therapies previously available only abroad or in private facilities.
What Makes Lutetium‑177 PSMA Therapy a Breakthrough?
Lutetium‑177 PSMA therapy is a highly precise form of targeted radiation treatment. It works by combining:
- Lutetium‑177, a therapeutic radioactive isotope
- PSMA‑targeting molecules, which seek out prostate cancer cells
This combination allows radiation to be delivered directly to cancer cells, sparing most surrounding healthy tissue.
Key Benefits for Patients
- Highly targeted treatment that attacks cancer at the molecular level
- Fewer side effects compared to chemotherapy and hormone therapy
- Greater precision and effectiveness for advanced or metastatic prostate cancer
- Now available locally at KUTRRH, reducing costs and eliminating the need for overseas treatment
This therapy is especially valuable for patients who have not responded well to conventional treatments.
Who Is an Ideal Candidate for Lutetium‑177 PSMA Therapy?
This advanced therapy is recommended for:
- Patients with advanced or metastatic prostate cancer
- Individuals whose cancer has progressed despite hormone therapy
- Patients currently on chemotherapy or those who cannot tolerate chemotherapy
Before treatment, each patient undergoes a PSMA PET scan at KUTRRH to confirm eligibility. This ensures the therapy is provided only to those most likely to benefit—reflecting the hospital’s commitment to personalised, evidence‑based care.
A Major Step Forward for Public Healthcare
“This advancement showcases KUTRRH’s dedication to providing world-class cancer treatment in a public institution,” said Dr. Zeinab Gura, CEO of KUTRRH. “It allows more patients to access life-extending, personalised care right here at home.”
Historically, therapies like Lutetium‑177 PSMA were available only in private or international facilities, creating financial and logistical challenges for many families.
KUTRRH’s adoption of this technology represents a powerful shift toward equitable cancer care and supports Kenya’s vision for Universal Health Coverage (UHC).
Investing in the Future of Cancer Care
KUTRRH continues to invest in world-class oncology services—including modern equipment, advanced diagnostics, and specialised expertise—to improve outcomes and make high-quality cancer treatment more affordable.
With prostate cancer ranking among the top causes of cancer-related deaths in men worldwide, offering Lutetium‑177 PSMA therapy within the region is a major step forward for Kenya and East Africa.
This achievement reinforces KUTRRH’s role as a regional hub for advanced medical research and specialised treatment.
Why This Matters
The introduction of Lutetium‑177 PSMA therapy is more than a medical innovation—it is a symbol of progress in public health.
It ensures that life-saving treatment is:
- Affordable
- Accessible
- High‑quality
- Delivered locally by experts
KUTRRH’s pioneering efforts ensure that advanced prostate cancer patients in Kenya and East Africa no longer need to seek costly treatment abroad—and can instead receive world‑class care close to home.
